A truly novel approach to studying women's biology and health: Deovo.
Many of today’s drugs have not been tested in women.
Clinical trials have only been required to include women since 1993. Many products used today are understudied in women, leading to severe side effects and low efficacy.
Diseases of the female reproductive system are understudied and have particularly poor animal models, as many of these diseases and conditions don’t occur naturally in animals. These diseases typically have no targeted treatments, leaving patients struggling.
Deovo: an in vitro organoid model of the female reproductive system.
We are developing Deovo, an engineered model of the female reproductive system to improve the drug development process for women.
Deovo is an organoid platform of the female reproductive system for disease modeling, drug discovery, and safety testing.
Our goal is more efficient development of therapeutics designed for the female reproductive system, as well as safety screening for all drugs entering clinical trials.
- High-throughput ovarian toxicity screening
- Precision medicine drug development
- Disease models
- Epigenetic modeling across organ systems
Study demonstrates the generation of ovarian support cells (OSCs) from hiPSCs through the induced expression of specific transcription factors
Our study, conducted in partnership with the George Church Lab at The Wyss Institute of Harvard Medical School, describes a novel protocol to generate granulosa-like cells through targeted transcription factor over-expression.
This paper generated a functional, follicle-producing ovarian organoid in vitro as proof-of-concept for the Deovo program.